All HHS Contracts — June 10, 2026
The two HHS contracts totaling $218.2 million reveal a civilian-focused procurement stream with a biodefense and public health services tilt, though only one of the two is defense-related (BARDA). The highest-conviction signal is Tunnell Consulting Inc.'s $92.8 million BARDA delivery order (potential $660.2M with options through 2035), indicating sustained government investment in biotech R&D and pandemic preparedness, but the company is private, limiting direct equity exposure. The Icahn School of Medicine's $125.5 million CDC contract is a low-margin, cost-no-fee award that has already ended, offering no future revenue upside. Key risk: Tunnell's labor-hours pricing structure shifts cost overrun risk to the contractor, and the Icahn contract's outlay rate is only 26% of the total obligation, suggesting potential under-execution or budget constraints.